External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology AACR 2025
Roche and Genentech at

AACR 2025

April 25 - April 30
Illinois, USA
aacr.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
08:00 PM
Duration 120hrs Illinois, USA
Contemporary Incidence of Gastroesophageal Junction and Gastric Cancers in the United States, 2016-2021 the United States, 2016-2021
Jessie Yan
Oncology | Gastroesophageal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:00 PM
Duration 15mins Illinois, USA
A phase I study evaluating safety, pharmacokinetics, and clinical activity of the novel, paradox breaker BRAF inhibitor RG6344 in patients with BRAF V600-mutant solid tumors
Maria Vieito, Elisa Fontana, Catherine Han, Eduardo Castanon, David J Pinato, Oliver Bechter, Irene Moreno, Rikke L Eefsen, Ruth Plummer, Reinhard Dummer, Hans Prenen, Giulia Pretelli, Gabriel Schnetzler, Piergiorgio Pettazzoni, Abiraj Keelara, David Dejardin, Andreas Roller, Ernesto Guarin, Elisa Cinato, Tomi Fakolade, Nino Keshelava, Ting Liu, Nick Flinn, Nicole A. Kratochwil
Oncology | Solid Tumours

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 180mins Illinois, USA
Divarasib plus migoprotafib combination treatment in patients with KRAS G12C-positive non- small cell lung cancer (NSCLC)
Jia Luo
Oncology | Solid Tumours

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:15 PM
Duration 15mins Chicago
SKYSCRAPER-01: a phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC
Peters S, Herbst R, Horinouchi H, Paz-Ares L, Johnson M, Solomon B, Gumus M, Erman M, Bondarenko I, KIm D-W, Felip E, Morabito A, Bryl M, Meng R, Stroud C, Kundu P, Wen P, Patil N, Huang M, Cho B-C
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:00 PM
Duration 180mins Illinois, USA
Unsupervised machine learning clustering based on consensus non-negative matrix factorization using mutational data identified novel genomic molecular subtypes in the 1L NSCLC study BFAST
Habib Hamidi
Oncology | Solid Tumours

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 180mins Illinois, USA
Phase Ib/II open-label, randomized study of atezolizumab + regorafenib + AB928 or atezolizumab + regorafenib vs regorafenib for patients with microsatellite-stable refractory metastatic colorectal cancer in MORPHEUS-CRC
J. Cleary, C. Gomez-Roca, F. Ghringhelli, J. O. Park, T-Y Kim, B. Beagle, J. Soong, Y. Yan, H-J Helms, J. Lau, E. Cha, M. Ducreux
Oncology | Colorectal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.